Overview
- Lakewood-Amedex announced on July 22, 2026 that serial passage experiments showed Nu-3 did not induce bacterial resistance in vitro.
- Nu-3 is a membrane-disrupting Bisphosphocin candidate described as Phase 2-ready for mildly infected diabetic foot ulcers, but the company has not announced a Phase 2 start date.
- Company laboratory profiling reported in vitro activity against 14 bacterial species, including E. coli, S. aureus, P. aeruginosa, K. pneumoniae and A. baumannii, and against resistance mechanisms such as NDM, ESBL, AmpC, CRE, vanA/vanB, mec variants and efflux pumps.
- The July 22 data release drove a roughly 141% one-day jump in LABT shares, highlighting investor interest even as Lakewood-Amedex remains a very small, pre-revenue biotech with a market cap near $3.3 million.
- The company framed the findings as aligned with PACCARB and the U.S. National Action Plan on antimicrobial resistance, but experts note that in vitro and serial passage results are early signals that do not guarantee clinical efficacy or absence of resistance in patients and that trials, regulatory review and financing are the next critical steps.